Scribe’s one-dose approach keeps cholesterol down for years
Scribe Therapeutics presents preclinical data on STX-1150 and STX-1200 at the AHA Scientific Sessions in Chicago. Two years is a long time to ask a single injection to do anything. Scribe Therapeutics says one dose of its experimental therapy STX-1150 kept LDL cholesterol under control for at least
<p>Scribe Therapeutics presents preclinical data on STX-1150 and STX-1200 at the AHA Scientific Sessions in Chicago. Two years is a long time to ask a single injection to do anything. Scribe Therapeutics says one dose of its experimental therapy STX-1150 kept LDL cholesterol under control for at least </p>